Arcutis Biotherapeutics Inc Ordinary Shares ARQT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
Arcutis Appoints Rob Scott, MD to Board of Directors
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
Trading Information
- Previous Close Price
- $34.05
- Day Range
- $25.78–29.49
- 52-Week Range
- $19.30–34.80
- Bid/Ask
- $25.00 / $27.54
- Shares Outstanding
- 126.46M
- Market Cap
- $3.39B
- Volume/Avg
- 8M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 128.57
- Price/Sales
- 7.12
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 354
- Website
- https://www.arcutis.com
Valuation
Metric | ARQT |
|---|---|
Price/Earnings (Normalized) | 128.57 |
Price/Book Value | 13.95 |
Price/Sales | 7.12 |
Price/Cash Flow | 45.20 |
Price/Earnings
ARQT
Financial Strength
Metric | ARQT |
|---|---|
Quick Ratio | 2.50 |
Current Ratio | 2.92 |
Interest Coverage | 2.56 |
Quick Ratio
ARQT
Profitability
Metric | ARQT |
|---|---|
Return on Assets (Normalized) | 16.35% |
Return on Equity (Normalized) | 37.16% |
Return on Invested Capital (Normalized) | 25.03% |
Return on Assets
ARQT
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%x%%n@ | LOCK|>@!$@ | $138B | |||
| Moderna Inc MRNA | LOCK|f&!%H! | LOCK|!Y | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Z@&!L?& | LOCK|BHRdW | $93B | |||
| argenx SE ADR ARGX | LOCK|pW>SZ& | LOCK|%l | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|%#<c!bk | LOCK|Db | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|^^R>jC$R | LOCK|#$Rb^ | $30B | |||
| Incyte Corp INCY | LOCK|m?&f$c | LOCK|$N | $24B | |||
| BioNTech SE ADR BNTX | LOCK|v@PQxSS | LOCK|zK& | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|X<$r<pY | LOCK|#Z#r | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|ddqF%& | LOCK|<F | $15B |
United States